Myomo, Inc. (MYO)
USD 4.44
(2.3%)
USD 4.44
(2.3%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 115.16 Thousand USD | -42.48% |
| 2022 | 200.2 Thousand USD | -50.15% |
| 2021 | 401.62 Thousand USD | 158.86% |
| 2020 | 155.14 Thousand USD | -82.55% |
| 2019 | 888.96 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 3.38 Million USD | 129.21% |
| 2015 | 1.47 Million USD | 11.82% |
| 2014 | 1.32 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 64.59 Thousand USD | 0.0% |
| 2024 Q2 | 47.33 Thousand USD | 0.0% |
| 2023 FY | 115.16 Thousand USD | -42.48% |
| 2023 Q4 | 115.16 Thousand USD | -54.52% |
| 2023 Q3 | 253.21 Thousand USD | 81.31% |
| 2023 Q2 | 139.65 Thousand USD | -17.74% |
| 2023 Q1 | 169.77 Thousand USD | -15.2% |
| 2022 Q3 | 220.9 Thousand USD | -32.8% |
| 2022 Q4 | 200.2 Thousand USD | -9.37% |
| 2022 FY | 200.2 Thousand USD | -50.15% |
| 2022 Q1 | 453.07 Thousand USD | 12.81% |
| 2022 Q2 | 328.72 Thousand USD | -27.44% |
| 2021 Q3 | 474.18 Thousand USD | -15.76% |
| 2021 Q2 | 562.88 Thousand USD | -12.61% |
| 2021 FY | 401.62 Thousand USD | 158.86% |
| 2021 Q1 | 644.1 Thousand USD | 315.16% |
| 2021 Q4 | 401.62 Thousand USD | -15.3% |
| 2020 Q3 | - USD | -100.0% |
| 2020 FY | 155.14 Thousand USD | -82.55% |
| 2020 Q4 | 155.14 Thousand USD | 0.0% |
| 2020 Q2 | 77.89 Thousand USD | 0.0% |
| 2020 Q1 | - USD | -100.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | 888.96 Thousand USD | 0.0% |
| 2019 Q4 | 888.96 Thousand USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q3 | 1.29 Million USD | -10.55% |
| 2017 Q2 | 1.45 Million USD | -71.85% |
| 2017 FY | - USD | -100.0% |
| 2017 Q1 | 5.15 Million USD | 52.37% |
| 2017 Q4 | - USD | -100.0% |
| 2016 Q2 | 2.37 Million USD | 0.0% |
| 2016 FY | 3.38 Million USD | 129.21% |
| 2016 Q1 | - USD | -100.0% |
| 2016 Q4 | 3.38 Million USD | 0.0% |
| 2015 FY | 1.47 Million USD | 11.82% |
| 2015 Q4 | 1.47 Million USD | 0.0% |
| 2015 Q3 | 1.47 Million USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 FY | 1.32 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Abbott Laboratories | 13.59 Billion USD | 99.999% |
| Allurion Technologies Inc. | 2.3 Million USD | 95.006% |
| Artivion, Inc. | 305.53 Million USD | 99.962% |
| Avanos Medical, Inc. | 159.4 Million USD | 99.928% |
| Butterfly Network, Inc. | 22.83 Million USD | 99.496% |
| Butterfly Network, Inc. | 22.83 Million USD | 99.496% |
| Bio-Rad Laboratories, Inc. | 1.18 Billion USD | 99.99% |
| Boston Scientific Corporation | 8.96 Billion USD | 99.999% |
| CONMED Corporation | 971.48 Million USD | 99.988% |
| Edwards Lifesciences Corporation | 670 Million USD | 99.983% |
| Paragon 28, Inc. | 109.79 Million USD | 99.895% |
| Glaukos Corporation | 383.73 Million USD | 99.97% |
| Globus Medical, Inc. | 417.4 Million USD | 99.972% |
| Inspire Medical Systems, Inc. | 24.84 Million USD | 99.537% |
| Integer Holdings Corporation | 959.92 Million USD | 99.988% |
| Medtronic plc | 23.87 Billion USD | 100.0% |
| Nevro Corp. | 211.47 Million USD | 99.946% |
| Owlet, Inc. | 22 Thousand USD | -423.455% |
| Penumbra, Inc. | 220.9 Million USD | 99.948% |
| Vicarious Surgical Inc. | 13.78 Million USD | 99.165% |
| Smith & Nephew plc | 2.17 Billion USD | 99.995% |
| Sonendo, Inc. | 14.03 Million USD | 99.179% |
| STERIS plc | 3.12 Billion USD | 99.996% |
| Stryker Corporation | 10.9 Billion USD | 99.999% |
| Vapotherm, Inc. | 109.97 Million USD | 99.895% |
| Zimmer Biomet Holdings, Inc. | 4.86 Billion USD | 99.998% |